those companies hitting this minimum standard will take further advantage of the regulatory opportunity while others scramble to make the pivot...pretty clear those arriving with medications under regulatory approval will dominate the space
IHL will benefit here obviously and the adoption of this minimum standard is why the investment funds are focusing their attention in this space realising the exceptional financial dersik about to take place- combined with the US Bill for research and there is a real shift in the space
I noted there are more than 100 cbd related trials (168 to be exact ) booked for 2023 and that number is increasing
looking forward to the next few months and deep into 2023
glah
IHL Price at posting:
21.5¢ Sentiment: None Disclosure: Held